

About Spherix Global Insights

Spherix is the world’s leading Life Sciences market intelligence and advisory services firm, providing unrivaled knowledge and the most informed, actionable insights.

We bring human intelligence to market intelligence. Spherix empowers customers to access critical insights that drive successful decision-making through deep, expert knowledge.



Spherix Provides Independent Expertise in Seven Areas



Dermatology



Nephrology



Gastroenterology



Neurology



Rheumatology



Ophthalmology



Hematology/Oncology

This is a guide to the publications Spherix will produce in 2024. It is organized by therapeutic area, indication, and deliverable.

Going Beyond the Data

The report is only the beginning. Spherix brings curation and interpretation to market intelligence, working closely with customers to reveal actionable insights that transform markets.

Type of Publications

MARKET DYNAMIX

A yearly market overview of an indication, Market Dynamix provides insights into current treatment paradigms and unmet patient needs as well as physician opinions on how they will likely prescribe new products upon approval.

REALTIME DYNAMIX

A US quarterly or EU5 semi-annual update on an indication, RealTime Dynamix provides trending content on brand use, future intentions, promotional activity, disease awareness and controversy, and pipeline product perceptions.

LAUNCH DYNAMIX

Published monthly, Launch Dynamix tracks a new brand’s first eighteen months of commercial availability. Each quarter includes a deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.

PATIENT CHART DYNAMIX

A yearly large-scale patient chart audit on an indication, Patient Chart Dynamix unmaskes real patient management patterns and uncovers the “why” behind treatment decisions.

PATIENT VOICE DYNAMIX

An independent service that explores the voice of the patient as they progress through their disease and treatment journeys.

PAYER DYNAMIX

Empowers pharmaceutical companies with forward-looking insights from key payer decision makers – enabling market access, brand, and strategy teams to confidently navigate evolving coverage and reimbursement landscapes, while preparing for potential policy-driven disruptions.

SPECIAL TOPIX

Whether the focus is breaking industry news, ongoing trends, conference coverage, or quick-pulse reactions, Special Topix assesses the impact of events in our specialty markets.

For a complete index of available reports, visit www.clientportal.spherixglobalinsights.com



Alopecia Areata

MARKET DYNAMIX	Alopecia Areata, US
LAUNCH DYNAMIX	Leqselvi (SUN Pharma) in Alopecia Areata, US

Atopic Dermatitis

MARKET DYNAMIX	- Atopic Dermatitis, US - Atopic Dermatitis, JP
REALTIME DYNAMIX	Atopic Dermatitis, EU5
LAUNCH DYNAMIX	- Ebglyss (Eli Lilly) in Atopic Dermatitis, US - Nemluvio (Galderma) in Atopic Dermatitis, US - Vtama and Zoryve (Organon/ Arcutis) in Atopic Dermatitis, US
PATIENT CHART DYNAMIX	Atopic Dermatitis, US
PATIENT VOICE DYNAMIX	Atopic Dermatitis, US

Chronic Spontaneous Urticaria

MARKET DYNAMIX	Chronic Spontaneous Urticaria, US
LAUNCH DYNAMIX	- Dupixent (Sanofi/Regeneron) in CSU, US - Rhapsido (Novartis) in CSU, US
PATIENT CHART DYNAMIX	Chronic Spontaneous Urticaria, US

Cross Indications / Specialty

SPECIAL TOPIX	- Biologic Coordinators Across Dermatology, US - Payer Management Strategies, US
---------------	--

Hidradenitis Suppurativa

MARKET DYNAMIX	- Hidradenitis Suppurativa, US - Hidradenitis Suppurativa, EU5
LAUNCH DYNAMIX	Bimzelx (UCB) in Hidradenitis Suppurativa, US

Plaque Psoriasis

REALTIME DYNAMIX	- Plaque Psoriasis, US - Plaque Psoriasis, EU5
LAUNCH DYNAMIX	Icotrokinra (J&J) in Plaque Psoriasis, US
PATIENT VOICE DYNAMIX	Plaque Psoriasis, US
SPECIAL TOPIX	The Oral Opportunity in Plaque Psoriasis, US

Prurigo Nodularis

MARKET DYNAMIX	Prurigo Nodularis, US
LAUNCH DYNAMIX	Nemluvio (Galderma) in Prurigo Nodularis, US

Other Dermatology Indications

MARKET DYNAMIX	- Asthma, US - Asthma, EU - Chronic Obstructive Pulmonary Disease, US - Chronic Obstructive Pulmonary Disease, EU - Vitiligo, US
----------------	--

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Eosinophilic Esophagitis

MARKET
DYNAMIX

- Eosinophilic Esophagitis, US

Inflammatory Bowel Disease

MARKET
DYNAMIX

- Crohn's Disease, JP
- Ulcerative Colitis, JP

REALTIME
DYNAMIX

- Crohn's Disease, US
- Crohn's Disease, EU5
- Ulcerative Colitis, US
- Ulcerative Colitis, EU5

LAUNCH
DYNAMIX

- Tremfya (Janssen) in Crohn's Disease, US
- Omvoh (Eli Lilly) in Crohn's Disease, US
- Tremfya (Janssen) in Ulcerative Colitis, US

PATIENT CHART
DYNAMIX

- Inflammatory Bowel Disease New Starts, US
- Inflammatory Bowel Disease Switching, US
- Inflammatory Bowel Disease Switching, EU5

PATIENT VOICE
DYNAMIX

- Inflammatory Bowel Disease, US

SPECIAL
TOPIX

- Biologic Coordinators in Gastroenterology, US
- The Role of APPs in IBD

Obesity

MARKET
DYNAMIX

- Obesity, US

LAUNCH
DYNAMIX

- Oral Semaglutide (Novo Nordisk) in Obesity, US
- Orforglipron (Eli Lilly) in Obesity, US
- CagriSema (Novo Nordisk) in Obesity, US

MASH

MARKET
DYNAMIX

- MASH, US
- MASH, EU5

LAUNCH
DYNAMIX

- Rezdiffra (Madrigal) in MASH, US
- Wegovy (Novo Nordisk) in MASH, US

PATIENT CHART
DYNAMIX

- MASH, US

SPECIAL
TOPIX

- MASH Screening and Management among PCPs and Endocrinologists, US

Other Gastroenterology Indications

MARKET
DYNAMIX

- Celiac Disease, US

REALTIME
DYNAMIX

- Irritable Bowel Syndrome, US

LAUNCH
DYNAMIX

- Iqirvo (Ipsen) in Primary Biliary Cholangitis, US
- Linerixibat (GSK) in Cholestatic Pruritus Among PBC Patients, US
- Livdelzi (Gilead/ Cymabay) in Primary Biliary Cholangitis, US

SPECIAL
TOPIX

- The Business of Gastroenterology, US

Cross Specialty

SPECIAL
TOPIX

- Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Lupus	
MARKET DYNAMIX	• Cutaneous Lupus, US (2026 refresh) • Systemic Lupus Erythematosus, US • Systemic Lupus Erythematosus Pipeline Refresh, US • Systemic Lupus Erythematosus, EU5 • Lupus Nephritis, China
REALTIME DYNAMIX	• Lupus Nephritis, US • Lupus Nephritis, EU5 • Lupus Nephritis, Brazil • Lupus Nephritis, Canada
LAUNCH DYNAMIX	• Gazyva (Genentech) in Lupus Nephritis, US
PATIENT CHART DYNAMIX	• Lupus Nephritis, US • Systemic Lupus Erythematosus , US • Systemic Lupus Erythematosus & Lupus Nephritis, EU5 • Cutaneous Lupus, US
PATIENT VOICE DYNAMIX	• Systemic Lupus Erythematosus & Lupus Nephritis, US

Spondyloarthritis (AS, nr-AxSpA, and PsA)	
MARKET DYNAMIX	• Ankylosing Spondylitis & nr-AxSpA, US • Ankylosing Spondylitis & nr-AxSpA, EU5 (2025) • Psoriatic Arthritis, EU5 (2025)
REALTIME DYNAMIX	• Psoriatic Arthritis, US
LAUNCH DYNAMIX	• Bimzelx (UCB) in AS & nr-AxSpA, US • Bimzelx (UCB) in Psoriatic Arthritis, US • Sotyktu (BMS) in Psoriatic Arthritis, US*

Other Rheumatology Indications	
MARKET DYNAMIX	• Idiopathic Inflammatory Myopathies, US (2026 Refresh) • Rheumatoid Arthritis, US (2026 Refresh) • Rheumatoid Arthritis, EU5 (2025) • Sjogren's Disease, US (2025) • Systemic Sclerosis, US
LAUNCH DYNAMIX	• Rinvoq (AbbVie) in Giant Cell Arteritis, US • Ianalumab (Novartis) in Sjogren's Disease, US*
PATIENT VOICE DYNAMIX	• Systemic Sclerosis, US
SPECIAL TOPIX	• ILD in Rheumatology, US (2026 Refresh) • Cell Therapy in Rheumatology, US • Biologic Coordinators Across Rheumatology, US
Cross Specialty	
SPECIAL TOPIX	• Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Rare Disease	
MARKET DYNAMIX	- Focal Segmental Glomerulosclerosis, US - Membranous Nephropathy, US
REALTIME DYNAMIX	- IgA Nephropathy, US - IgA Nephropathy, EU5
LAUNCH DYNAMIX	- Fabhalta in C3G - Empaveli in C3G - Fabhalta in IgAN - Vanrafia in IgAN - Sibeprenlimab in IgAN - Filspari in FSGS* - Atacicept in IgAN* - Povetacicept in IgAN*
PATIENT CHART DYNAMIX	- Focal Segmental Glomerulosclerosis, US - IgA Nephropathy, US - IgA Nephropathy, EU5 - IgA Nephropathy, JP - IgA Nephropathy, China
PATIENT VOICE DYNAMIX	IgA Nephropathy, US

CKD, Dialysis & Transplant	
MARKET DYNAMIX	Transplant/AMR, US
REALTIME DYNAMIX	- Dialysis–Nephrologists, US - Dialysis, Renal Dietitians/NP/PA, US
LAUNCH DYNAMIX	- Vafseo (Akebia) in Renal Anemia, US - OLC (Unicycive) in Hyperphosphatemia, US*
PATIENT CHART DYNAMIX	- Chronic Kidney Disease, Non-Dialysis, Nephrologists, US - Chronic Kidney Disease, Non-Dialysis, PCPs, US - Dialysis, US
PATIENT VOICE DYNAMIX	Chronic Kidney Disease, US
SPECIAL TOPIX	Feedback from ASN Kidney Week, US

Cross Specialty	
SPECIAL TOPIX	Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas

*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



Alzheimer's Disease

MARKET
DYNAMIX

- Alzheimer's Disease, US

PATIENT VOICE
DYNAMIX

- Alzheimer's Disease, US

Migraine

REALTIME
DYNAMIX

- Migraine, 2 Wave, US

Multiple Sclerosis

MARKET
DYNAMIX

- Multiple Sclerosis, US

LAUNCH
DYNAMIX

- Tolebrutinib, (Sanofi) nrSPMS, US

Psychiatric Indications

MARKET
DYNAMIX

- Psychosis in Schizophrenia, US
- Major Depressive Disorder (MDD), US
- Schizophrenia, US

Generalized Myasthenia Gravis

REALTIME
DYNAMIX

- Generalized Myasthenia Gravis, US
- Generalized Myasthenia Gravis, EU5

PATIENT CHART
DYNAMIX

- Generalized Myasthenia Gravis, US
- Generalized Myasthenia Gravis, EU5

PATIENT VOICE
DYNAMIX

- Generalized Myasthenia Gravis, US

LAUNCH
DYNAMIX

- Uplizna, (Amgen) Generalized Myasthenia Gravis (gMG), US
- Imaavy, (J&J) Generalized Myasthenia Gravis (gMG), US
- Gefurulumab, (Alexion/AZ) Generalized Myasthenia Gravis (gMG), US*
- Cemdisiran, (Regeneron) Generalized Myasthenia Gravis (gMG), US*

Other Neurology Indications

MARKET
DYNAMIX

- Chronic Inflammatory Demyelinating Polyneuropathy, US

SPECIAL
TOPIX

- Cell Therapy in Neurology Indications, US

Cross Specialty

SPECIAL
TOPIX

- Payer Management Strategies, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



Diabetic Macular Edema & Neovascular Age-Related Macular Degeneration

REALTIME DYNAMIX	Diabetic Macular Edema & AMD, US
------------------	--

Cross Specialty

SPECIAL TOPIX	Payer Management Strategies, US
---------------	---

Neovascular Age-Related Macular Degeneration

PATIENT CHART DYNAMIX	Age-Related Macular Degeneration, US
-----------------------	--

Other Ophthalmology Indications

MARKET DYNAMIX	Diabetic Retinopathy, US
SPECIAL TOPIX	Gene Therapies in Retina, US

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas



B-Cell Malignancies

MARKET DYNAMIX	- B-Cell Malignancies, US - Large B-Cell Lymphoma, EU
PATIENT CHART DYNAMIX	- Large B-Cell Lymphoma, US - Chronic Lymphocytic Leukemia, US
PATIENT VOICE DYNAMIX	B-Cell Malignancies, US

Bleeding Disorders

MARKET DYNAMIX	- Hemophilia A & B, US - Hemophilia A & B, EU5 - Von Willebrand Disease, US
LAUNCH DYNAMIX	- Qfitlia in Hemophilia A & B - Hypmavzi in Hemophilia A & B - Alhemo in Hemophilia A & B
PATIENT VOICE DYNAMIX	People with Bleeding Disorders
SPECIAL TOPIX	Women, Girls, and people who have or have had the potential to menstruate (WGPPM) with Bleeding Disorders

Hemoglobinopathies

MARKET DYNAMIX	- Sickle Cell Disease, US - Thalassemia, US
LAUNCH DYNAMIX	Mitapivat in Thalassemia*
PATIENT CHART DYNAMIX	- Sickle Cell Disease, US - Thalassemia, US
PATIENT VOICE DYNAMIX	Sickle Cell Disease, US

Cross Specialty

SPECIAL TOPIX	Payer Management Strategies, US
---------------	---

Solid Tumors

REALTIME DYNAMIX	PD-1 Inhibition in Solid Tumors, US
------------------	---

Multiple Myeloma

MARKET DYNAMIX	Multiple Myeloma, EU5
REALTIME DYNAMIX	Multiple Myeloma, US
PATIENT CHART DYNAMIX	Multiple Myeloma, US
PATIENT VOICE DYNAMIX	Multiple Myeloma, US
SPECIAL TOPIX	Smoldering Myeloma, US

Acute Myeloid Leukemia

REALTIME DYNAMIX	Acute Myeloid Leukemia, US
PATIENT CHART DYNAMIX	Acute Myeloid Leukemia, US

Myeloproliferative Neoplasms (MPN)

MARKET DYNAMIX	Myeloproliferative Neoplasms, US
----------------	--

Paroxysmal Nocturnal Hemoglobinuria

MARKET DYNAMIX	Paroxysmal Nocturnal Hemoglobinuria, US
PATIENT CHART DYNAMIX	Paroxysmal Nocturnal Hemoglobinuria, US

Other Benign Hematology Indications

MARKET DYNAMIX	- Warm Autoimmune Hemolytic Anemia (w-AIHA) - Immune Thrombocytopenic Purpura (ITP)
LAUNCH DYNAMIX	- Nipocalimab in w-AIHA* - Wayrilz in ITP

Key

MARKET DYNAMIX	Yearly market overview of key indication
REALTIME DYNAMIX	Quarterly (US) or semi-annual (EU5) indication updates
LAUNCH DYNAMIX	Monthly benchmark of newly launched products
PATIENT CHART DYNAMIX	Yearly review of large-scale patient chart audits
PATIENT VOICE DYNAMIX	Independent service capturing patient journey insights
PAYER DYNAMIX	Payer priorities and tactics compared across therapy areas
SPECIAL TOPIX	Current events on specific interest areas

*Pending approvals and launch

Publications may change due to factors such as FDA approval status and other market events



**Looking for more?
Visit the Spherix Portal**

The Spherix Portal helps clients interact with their data and insights so they can find answers to their important questions.

By using the portal, Spherix clients can access all their subscribed data and easily integrate intelligence into their research projects.

Access to the Spherix Portal is open to anyone. It's the best way to find the right product to fit your needs.

**Create your free account at
www.clientportal.spherixglobalinsights.com**